Long-term clinical outcomes of Zika-associated Guillain-Barré syndrome

Emerg Microbes Infect. 2018 Aug 22;7(1):148. doi: 10.1038/s41426-018-0151-9.

Authors

Aileen Y Chang¹, Rebecca Lynch², Karen Martins³, Liliana Encinales³, Andrés Á Cadena Bonfanti^{4

5}, Nelly Pacheco⁶, St Patrick Reid⁷, Osvaldo E Lara Sarabia^{4

5}, Henry J González Torres⁴, Stella Mejia Castillo⁴, Onaldo Barrios Taborda⁴, Magda Alarcon Gomez⁴, Brenda Guerra Duran⁴, Victor Martinez Giraldo⁵, Angélica Benitez Ospino⁵, Alexandra Porras⁸, Alejandro R Mendoza⁸, Grace Mantus², Guangzhao Li², Jin Peng², Priyanka Kamalapathy², Lil G Avendaño Echavez⁴, Kimberly A Dowd⁹, Monica Rengifo-Pardo², Pedro Pablo Barraza⁶, Dennys Jiménez Hernàndez⁵, Andrés González Coba⁵, Katya De La Hoz Mendoza⁵, Jeffrey M Bethony², Gary L Simon²

Affiliations

¹ The George Washington University, Washington, DC, 20037, USA. chang@email.gwu.edu.
² The George Washington University, Washington, DC, 20037, USA.
³ United States Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD, USA.
⁴ Universidad Simón Bolívar, Barranquilla, Atlántico, Colombia.
⁵ Clinica de La Costa Ltda, Baranquilla, Atlántico, Colombia.
⁶ Allied Research Society LLC, Baranquilla, Atlántico, Colombia.
⁷ University of Nebraska Medical Center, Omaha, NE, USA, 68182.
⁸ Universidad El Bosque, Bogotá, Colombia.
⁹ National Institutes of Health, Bethesda, MD, USA, 20892.

No abstract available

MeSH terms

Disability Evaluation
Female
Follow-Up Studies
Guillain-Barre Syndrome / etiology
Guillain-Barre Syndrome / virology*
Humans
Male
Middle Aged
Time Factors
Zika Virus / immunology
Zika Virus / pathogenicity
Zika Virus Infection / cerebrospinal fluid*
Zika Virus Infection / complications*
Zika Virus Infection / immunology

Grants and funding